文献速递系统性红斑狼疮

非肾性系统性红斑狼疮患者中贝利尤单抗与口服免疫抑制剂感染风险的比较

Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2023-10-08

该研究利用美国多中心电子健康记录数据库的观察性数据,纳入2011至2021年非肾性系统性红斑狼疮(SLE)患者,采用模拟目标试验设计,比较贝利尤单抗与硫唑嘌呤、甲氨蝶呤、吗替麦考酚酯的严重感染及感染住院风险。结果显示,与硫唑嘌呤和吗替麦考酚酯相比,贝利尤单抗与较低的严重感染风险和感染住院风险相关;与甲氨蝶呤相比,贝利尤单抗的感染风险也较低。各治疗组间创伤性损伤风险无差异。

要点

  • 贝利尤单抗较硫唑嘌呤的严重感染HR为0.82(95%CI 0.72-0.92),感染住院HR为0.73(95%CI 0.57-0.94)。
  • 贝利尤单抗较吗替麦考酚酯的严重感染HR为0.69(95%CI 0.61-0.78),感染住院HR为0.56(95%CI 0.43-0.71)。
  • 贝利尤单抗较甲氨蝶呤的感染风险亦较低(HR 0.86;95%CI 0.76-0.97)。

核心结论

  • 贝利尤单抗与口服免疫抑制剂相比,与较低的严重感染风险相关。
  • 该发现应为SLE治疗的风险/获益考量提供参考。

研究设计与样本

  • 利用美国多中心电子健康记录数据库的观察性数据,识别2011至2021年期间无狼疮肾炎的SLE患者。
  • 设计并模拟目标试验,比较贝利尤单抗与硫唑嘌呤、甲氨蝶呤或吗替麦考酚酯新使用者。
  • 采用倾向评分重叠权重平衡基线协变量,并使用逆概率治疗加权调整治疗依从性。
  • 同时评估创伤性损伤作为控制结局。

主要发现

  • 共纳入21,481例患者;贝利尤单抗与硫唑嘌呤比较组分别为2841例和6343例,贝利尤单抗与甲氨蝶呤比较组分别为2642例和8242例,贝利尤单抗与吗替麦考酚酯比较组分别为2813例和8407例。
  • 倾向评分重叠加权后,各比较中所有协变量均平衡;队列平均年龄45岁,94%为女性。
  • 与硫唑嘌呤相比,贝利尤单抗的严重感染HR为0.82(95%CI 0.72-0.92),感染住院HR为0.73(95%CI 0.57-0.94)。
  • 与吗替麦考酚酯相比,贝利尤单抗的严重感染HR为0.69(95%CI 0.61-0.78),感染住院HR为0.56(95%CI 0.43-0.71)。
  • 与甲氨蝶呤相比,贝利尤单抗的感染风险亦较低(HR 0.86;95%CI 0.76-0.97);各治疗组间创伤性损伤风险无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated the comparative risk of infection with belimumab versus oral immunosuppressants for the treatment of systemic lupus erythematosus (SLE). METHODS: Using observational data from a US multicenter electronic health record database, we identified patients with SLE but without lupus nephritis who initiated belimumab, azathioprine, methotrexate, or mycophenolate between 2011 and 2021. We designed and emulated hypothetical target trials to estimate the cumulative incidence and hazard ratios (HRs) of serious infection and hospitalization for serious infection comparing belimumab versus each oral immunosuppressant. We used propensity score overlap weighting to balance baseline covariates and adjusted for adherence to treatment group using inverse probability of treatment weighting. We also assessed the control outcome of traumatic injury. RESULTS: Among 21,481 patients, we compared 2841 and 6343 initiators of belimumab and azathioprine, 2642 and 8242 initiators of belimumab and methotrexate, and 2813 and 8407 initiators of belimumab and mycophenolate, respectively. After propensity score overlap weighting, all covariates were balanced in each comparison. The mean age of the cohort was 45 years, and 94% were women. Compared with azathioprine and mycophenolate, belimumab was associated with lower risks of both serious infection (HR 0.82; 95% confidence interval [CI] 0.72-0.92 and HR 0.69; 95% CI 0.61-0.78) and hospitalization for infection (HR 0.73; 95% CI 0.57-0.94 and HR 0.56 95% CI 0.43-0.71). The risk of infection was also lower for belimumab compared with methotrexate (HR 0.86; 95% CI 0.76-0.97). There were no differences in traumatic injury risks across treatment groups. CONCLUSION: Belimumab was associated with lower risks of serious infection than with oral immunosuppressants. This finding should inform risk/benefit considerations for SLE treatment.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Materne E, Choi H, Zhou B, et al. Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus. Arthritis Rheumatol. 2023. PMID: 37262382. doi:10.1002/art.42620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。